Odia, Y., Hall, M., ..., Daghistani, D., et al (2024). Selective DRD2 antagonist and ClpP agonist ONC201 in a recurrent non-midline H3 K27M-mutant glioma cohort. Neuro-oncology, 26 (Suppl 2), @S165-S172. View in Pubmed

Odia, Y., Koschmann, C., ..., Daghistani, D., et al (2024). Safety and pharmacokinetics of ONC201 (dordaviprone) administered two consecutive days per week in pediatric patients with H3K27M-mutant glioma. Neuro-oncology, 26 (Suppl 2), @S155-S164. View in Pubmed

Venneti, S., Kawakibi, A.R., ..., Daghistani, D., et al (2023). Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways. Neuro-oncology Advances, 13 (11), @2370-2393. View in Pubmed

Gardner, S.L., Tarapore, R.S., ..., Daghistani, D., et al (2022). Phase I dose escalation and expansion trial of single agent ONC201 in pediatric diffuse midline gliomas following radiotherapy. Neuro-oncology Advances, 4 (1), @vdac143. View in Pubmed